Invariant natural killer T-cell anergy to endogenous myelin acetyl-glycolipids in multiple sclerosis
View/ Open
Date
2013Author
Gately, Carol M.
Podbielska, Maria
Counihan, Timothy
Hennessy, Michael
Leahy, Teresa
Moran, Anthony P.
Hogan, Edward L.
O'Keeffe, Joan
Metadata
Show full item recordAbstract
Objective: To extend our studies on the glycolipid-reactive invariant Natural Killer T-cell (iNKT-cell) function in multiple sclerosis (MS), we investigated the stimulatory activities of two myelin-derived glycolipids which are poly-acetylated derivatives of β-galactosylceramide, designated PA-GC and FMC-7 (fast migrating cerebroside-7). Methods: Peripheral blood mononuclear cells from MS patients or healthy control subjects were stimulated with PA-GC, FMC-7 or α-galactosylceramide (α-GalCer). In cell expansion studies, the frequencies of iNKT-cells were analysed before and after glycolipid stimulation by flow cytometry. Analysis of cytokines in culture supernatants was performed using Th1/Th2 multiplexing and flow cytometry.
Results: In healthy subjects, the myelin-derived glycolipids significantly expanded iNKT-cells in a similar way to α-GalCer and induced significant increases of Th1, Th2 and Th17 cytokines in peripheral blood cultures. In marked contrast, MS patients failed to respond to either of the myelin-derived acetylated glycolipids or to α-GalCer stimulation indicating an anergic response.
Conclusions: We propose that myelin-derived glycolipids stimulate iNKT-cell responses in vivo and that regulation or inhibition of this response may determine the immune response or disease onset in the CNS.
Collections
The following license files are associated with this item: